Blincyto 35 mcg lyophilized powder for injection Images
Generic Name: blinatumomab
This medication has been identified as Blincyto 35 mcg lyophilized powder for injection and is used for Acute Lymphoblastic Leukemia. It belongs to the drug class bispecific T-cell engagers (BiTE) and is not a controlled substance.
Images of medication
Blincyto
- Generic Name
- blinatumomab
- Strength
- 35 mcg lyophilized powder for injection
- Availability
- Prescription only
- Drug Class
- Bispecific T-cell engagers (BiTE)
- Pregnancy Category
- C - Risk cannot be ruled out
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Amgen Inc.
- National Drug Code (NDC)
- 55513-0160
See also:
More about Blincyto (blinatumomab)
- Check interactions
- Compare alternatives
- Reviews (1)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: bispecific T-cell engagers (BiTE)
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.